ALT has been in the news 500% more than usual
Aug 13, 2025, 10:32 PM
0.80%
What does ALT do
Altimmune, a clinical-stage biopharmaceutical company in Gaithersburg, Maryland, develops peptide-based therapeutics for obesity and liver diseases, including the lead candidate pemvidutide. The company has completed Phase II trials for both pemvidutide and HepTcell, targeting metabolic dysfunction and hepatitis B.
ALT has been in the news recently: Berger Montague PC and Rosen Law Firm have both filed class action lawsuits against Altimmune Inc. due to significant stock declines and disappointing trial results reported between August 2023 and June 2025. Additionally, Altimmune reported a financial loss for the second quarter of 2025.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.